

T-5224

## Chemical Properties

CAS No. : 530141-72-1


Formula: C<sub>29</sub>H<sub>27</sub>N<sub>0</sub>O<sub>8</sub>

Molecular Weight: 517.53

Store at low temperature

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	T-5224 is a selective inhibitor of the transcription factor c-Fos/activator protein (AP)-1 with anti-inflammatory effects. T-5224 specifically suppresses the DNA-binding activity of c-Fos/c-Jun, thereby inhibiting IL-1 $\beta$ -induced transcriptional upregulation of Mmp-3, Mmp-13, and Adamts-5, without affecting the binding activity of other transcription factors. T-5224 can be used in research on rheumatoid arthritis, osteoarthritis, and cartilage degeneration.
Targets(IC50)	MMP,DNA/RNA Synthesis
In vitro	<p><b>Methods:</b> Human epidermal keratinocytes (NHEKs) were treated with T-5224 at concentrations ranging from 0.1 to 1 <math>\mu</math>M for 24 hours, followed by MTT assay to assess cell viability.</p> <p><b>Results:</b> Within this concentration range, T-5224 exhibited no cytotoxicity and did not affect cell proliferation. [1]</p> <p><b>Methods:</b> Add T-5224 at gradient concentrations (0, 20, 40, 80 <math>\mu</math>M) to HSC-3-M3 and OSC-19 cells. Measure cell migration area 24 hours after wounding.</p> <p><b>Results:</b> T-5224 exhibited dose-dependent inhibition of migration in both cell types, with migration nearly completely suppressed at 80 <math>\mu</math>M. [2]</p>
In vivo	<p><b>Methods:</b> Female BALB/c mice aged 8-10 weeks were used to establish a DNFB model. Following successful model establishment, topical application of 1% T-5224, 1% baricitinib, or 1% T-5224 + 1% baricitinib ointment was administered at 25 mg per ear, once daily for 8 days.</p> <p><b>Results:</b> T-5224 significantly suppressed inflammation and restored Flg expression. T-5224 restored Elovl6 expression. T-5224 specifically suppressed Il17a/Il17f. [1]</p> <p><b>Methods:</b> BALB/c nude mice were established with an orthotopic tumor model by injecting HSC-3-M3 cells (<math>1 \times 10^5</math>) into the tongue. T-5224 (150 mg/kg/day) was administered orally via gavage starting on day 1 post-tumor implantation, once daily for 4 consecutive weeks.</p> <p><b>Results:</b> No significant difference in primary tumor volume was observed between groups, and T-5224 had no apparent effect on body weight. Cervical lymph node metastasis rates were 74.1% (20/27) in the control group and 40.0% (12/30) in the T-5224-treated group, representing a significant difference.[2]</p>
Kinase Assay	The DNA binding activity of transcription factors was measured using the TransAM kits. Nuclear extracts containing factors such as c-Fos/AP-1, c-Jun/AP-1, ATF-2, C/EBPa,

Kinase Assay	MyoD, Sp-1 or NF-kB/p65 and various concentrations of T-5224 were added in the multi-well plates precoated with respective consensus double-stranded (ds)DNA oligomers. After incubation for 1 h, the transcription factor bound to its respective consensus dsDNA sequences was detected by using antibodies reactive against the respective transcription factors according to the manufacturer's protocol [1].
Cell Research	NIH/3T3 cells were transiently transfected with the luciferase reporter plasmids pAP-1-Luc ( $\times 7$ TGAATA), pNF-kB-Luc ( $\times 5$ TGGGGACTTTCCGC) or control pRL-TK, and cultured overnight. Cells were incubated in 0.5% FBS/DMEM containing T-5224 for 1 h, and then stimulated with PMA (10 ng/ml) or TNF $\alpha$ (10 ng/ml), and then cultured for 3 h, followed by measurement of lysate by using dual-luciferase reporter assay system [1].
Animal Research	Mice were housed in an SPF (specific pathogen-free) grade environment and provided food and water ad libitum with a 12 h:12 h light/dark cycle. Male 8-week-old DBA/1J mice were immunized with bovine type II collagen emulsified in Freund's complete adjuvant on days 0 and 21. T-5224, MTX and LEF were orally administered once per day. Arthritis was assessed in a blind fashion for four paws per mouse using the following score: 0, uninvolved; 1, swelling of $\leq 2$ toes or slight swelling in ankles and wrists; 2, swelling of $\geq 3$ toes or moderate swelling in ankles and wrists; 3, extensive swelling of total paw. X-ray films of four paws taken using Softex were assessed for joint destruction in 2nd to 5th proximal interphalangeal joints and five metatarsophalangeal joints of four paws, the carpal joints of the forepaws, and the tarsal and calcaneal joints of the hind paws. Score was: 0, no change; 1, partial erosion; 2, complete erosion for joints; and 0, negative; 0.5, positive for osteoporosis. IL-1 $\beta$ (500 ng per unilateral hind paw) was administered into the footpads. The mice with $\geq 1$ arthritis score were treated with either anti-TNF $\alpha$ antibody at 50 or 250 $\mu$ g/mouse, intraperitoneally (i.p.) twice a week and/or with 3 mg/kg T-5224, orally once daily [1].

## Solubility Information

Solubility	H <sub>2</sub> O: Insoluble, DMSO: 240 mg/mL (463.74 mM), Sonication is recommended. ( $< 1$ mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (9.66 mM), Suspension. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9323 mL	9.6613 mL	19.3226 mL
5 mM	0.3865 mL	1.9323 mL	3.8645 mL
10 mM	0.1932 mL	0.9661 mL	1.9323 mL
50 mM	0.0386 mL	0.1932 mL	0.3865 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

- Sasakura M, et al. Topical application of activator protein-1 inhibitor T-5224 suppresses inflammation and improves skin barrier function in a murine atopic dermatitis-like dermatitis. *Allergol Int.* 2024 Apr;73(2):323-331.
- Wang X, Li K, Cheng M, et al. RNPS1 stabilizes NAT10 protein to facilitate translation in cancer via tRNA ac4C modification. *bioRxiv.2023: 2023.02. 11.528122.*
- Zhang Q, Hui M, Chen G, et al. Curcumin-Piperlongumine Hybrid Molecule Increases Cell Cycle Arrest and Apoptosis in Lung Cancer through JNK/c-Jun Signaling Pathway. *Journal of Agricultural and Food Chemistry.* 2024
- Kamide D, et al. Selective activator protein-1 inhibitor T-5224 prevents lymph node metastasis in an oral cancer model. *Cancer Sci.* 2016 May;107(5):666-73.
- Blunsom NJ, et al. Sustained phospholipase C stimulation of H9c2 cardiomyoblasts by vasopressin induces an increase in CDP-diacylglycerol synthase 1 (CDS1) through protein kinase C and cFos. *Biochim Biophys Acta Mol Cell Biol Lipids.* 2019 Jul;1864(7):1072-1082.
- Kamide D, et al. Selective activator protein-1 inhibitor T-5224 prevents lymph node metastasis in an oral cancer model. *Cancer Sci.* 2016 May;107(5):666-73.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481